Last update July 25, 2017
Limited compatibility
We do not have alternatives for Dicycloverine.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Dicycloverine is also known as
Dicycloverine in other languages or writings:
Dicycloverine belongs to this group or family:
Main tradenames from several countries containing Dicycloverine in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Because of high protein-binding capacity, clinically significant excretion into breast milk is unlikely. However, both the mother and the infant would benefit of the use of a better-known alternative drug that would be safer while breastfeeding, especially in the neonatal period and in case of prematurity.
In spite of a low excretion into breast milk, it has been described a case of severe apnea in a 12 days old infant. A causal connection between those features and this drug has not been clearly defined (Briggs 2011, p. 410).
It is licensed for use in children from 6 months of age as intestinal antispasmodic and treatment of Familial Mediterranean Fever, so there would be less risky when used by the breastfeeding mother.